More articles from Companion Diagnostics and Cancer Biomarkers

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
Joo Ern Ang, Akos Pal, Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de haven Brandon, Victoria L. Revell, Debra J. Skene, Miro Venturi, Ruediger Rueger, Valerie Meresse, Suzanne A. Eccles, Johann S. de Bono, Stanley B. Kaye, Paul Workman, Udai Banerji, Florence I. Raynaud

Molecular Cancer Therapeutics Oct 2017, 16 (10) 2315-2323; DOI: 10.1158/1535-7163.MCT-16-0881
Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation
John K. Simmons, Aleksandra M. Michalowski, Benjamin J. Gamache, Wendy DuBois, Jyoti Patel, Ke Zhang, Joy Gary, Shuling Zhang, Snehal Gaikwad, Daniel Connors, Nicholas Watson, Elena Leon, Jin-Qiu Chen, W. Michael Kuehl, Maxwell P. Lee, Adriana Zingone, Ola Landgren, Peter Ordentlich, Jing Huang, Beverly A. Mock

Molecular Cancer Therapeutics Sep 2017, 16 (9) 2008-2021; DOI: 10.1158/1535-7163.MCT-17-0171
Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
Cristina Santos, Daniel Azuara, Rocio Garcia-Carbonero, Pilar Garcia Alfonso, Alfredo Carrato, Mª Elena Elez, Auxiliadora Gomez, Ferran Losa, Clara Montagut, Bartomeu Massuti, Valenti Navarro, Mar Varela, Adriana Lopez-Doriga, Victor Moreno, Manuel Valladares, Jose Luis Manzano, Jose Maria Vieitez, Enrique Aranda, Xavier Sanjuan, Josep Tabernero, Gabriel Capella, Ramon Salazar

Molecular Cancer Therapeutics Sep 2017, 16 (9) 1999-2007; DOI: 10.1158/1535-7163.MCT-17-0153
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
Jayaprakash D. Karkera, Gabriela Martinez Cardona, Katherine Bell, Dana Gaffney, Joseph C. Portale, Ademi Santiago-Walker, Christopher H. Moy, Peter King, Michael Sharp, Rastislav Bahleda, Feng R. Luo, John D. Alvarez, Matthew V. Lorenzi, Suso J. Platero

Molecular Cancer Therapeutics Aug 2017, 16 (8) 1717-1726; DOI: 10.1158/1535-7163.MCT-16-0518
Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate–Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma
Chia-Wen Liu, Kuo-Tai Hua, Kai-Chun Li, Hsiang-Fong Kao, Ruey-Long Hong, Jenq-Yuh Ko, Michael Hsiao, Min-Liang Kuo, Ching-Ting Tan

Molecular Cancer Therapeutics Jul 2017, 16 (7) 1421-1434; DOI: 10.1158/1535-7163.MCT-16-0567-T
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer
Young Kwang Chae, Andrew A. Davis, Sarika Jain, Cesar Santa-Maria, Lisa Flaum, Nike Beaubier, Leonidas C. Platanias, William Gradishar, Francis J. Giles, Massimo Cristofanilli

Molecular Cancer Therapeutics Jul 2017, 16 (7) 1412-1420; DOI: 10.1158/1535-7163.MCT-17-0061
PMP22 Regulates Self-Renewal and Chemoresistance of Gastric Cancer Cells
Wangyu Cai, Gang Chen, Qicong Luo, Jun Liu, Xiaofeng Guo, Tian Zhang, Fei Ma, Liang Yuan, Boan Li, Jianchun Cai

Molecular Cancer Therapeutics Jun 2017, 16 (6) 1187-1198; DOI: 10.1158/1535-7163.MCT-16-0750
Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology
Hatim Husain, David Nykin, Nam Bui, Daniel Quan, German Gomez, Brian Woodward, Sumathi Venkatapathy, Radha Duttagupta, Eric Fung, Scott M. Lippman, Razelle Kurzrock

Molecular Cancer Therapeutics May 2017, 16 (5) 948-955; DOI: 10.1158/1535-7163.MCT-16-0436
APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer
Noritaka Tanaka, Tetsuo Mashima, Anna Mizutani, Ayana Sato, Aki Aoyama, Bo Gong, Haruka Yoshida, Yukiko Muramatsu, Kento Nakata, Masaaki Matsuura, Ryohei Katayama, Satoshi Nagayama, Naoya Fujita, Yoshikazu Sugimoto, Hiroyuki Seimiya

Molecular Cancer Therapeutics Apr 2017, 16 (4) 752-762; DOI: 10.1158/1535-7163.MCT-16-0578
MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Peilong Li, Xin Zhang, Haiyan Wang, Lili Wang, Tong Liu, Lutao Du, Yongmei Yang, Chuanxin Wang

Molecular Cancer Therapeutics Apr 2017, 16 (4) 739-751; DOI: 10.1158/1535-7163.MCT-16-0591

Main menu

User menu

Search

More articles from Companion Diagnostics and Cancer Biomarkers

Pages

Articles

Info for

About MCT